Business
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence
About this update from Lantern Pharma Inc.
[{"type":"text","content":" DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting. Details on the AACR presentation are provided below:\n\n\nAACR Annual Meeting in Orlando, FL from April 14th-19th, 2023\n\n\nPoster Title: LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in DNA damage repair deficient cancers\n\n\nPresentation Date and Time: Wednesday, April 19, 2023 from 9:00 a.m. – 12:30 p.m. ET\n\n\nAbstract Link: https://www.abstractsonline.com/pp8/#!/10828/presentation/6762\n\n\nRegistration: https://www.aacr.org/meeting/aacr-annual-meeting-2023/registration/\n\n\nThe AACR presentation will focus on Lantern’s drug candidate LP-184 and its unique anti-cancer mechanism of action known as synthetic lethality. In oncology drug development, synthetic lethality has become a highly desired capability for small molecules as it promotes the selective anti-tumor toxicity of cancer cells, while reducing potential side effects to normal cells. This mechanism of action can exploit vulnerabilities in cancer cells, known as DNA damage repair deficiencies, which are common in 25-30% of solid tumors. Using synthetic lethality, Lantern’s drug candidate LP-184 has demonstrated nanomolar potency across a comprehensive number of in vitro and in vivo preclinical models in solid tumors as well as in adult and pediatric central nervous system cancers. Based on its synthetic lethality mechanism of action and strong preclinical results, Lantern is targeting advancing LP-184 to a first-in-human Phase 1 clinical trial in mid-2023.\n\nLantern will also be hosting a key opinion leader webinar on synthetic lethality on Tuesday, March 21, 2023 at 12:00 p.m. ET, featuring a leading expert in synthetic lethality, Zoltan Szallasi, M.D. Register for the webinar here.\n\nAbout Lantern Pharma\nLantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® AI and machine learning platform to discover biomarker signatures that identify patients most li...